T1	Participants 98 203	graft-versus-host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT).
T2	Participants 276 491	study conducted from 2000 to 2003 of palifermin, a recombinant human keratinocyte growth factor, dosed from 240 microg/kg to 720 microg/kg, in 100 allogeneic hematopoietic stem cell transplantation (HCT) recipients.
T3	Participants 1212 1238	allogeneic HCT recipients.
